⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CABA News
Cabaletta Bio, Inc. Common Stock
Cellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners Investment
businesswire.com
BMY
CABA
Form 8-K
sec.gov
CABA
Form 8-K
sec.gov
CABA
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
globenewswire.com
CABA
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA
OXB Capital Markets Event
globenewswire.com
CABA
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
globenewswire.com
MRK
SNY
AZN
REGN
JNJ
CABA
Form 8-K
sec.gov
CABA
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
CABA
Form 8-K
sec.gov
CABA